Davis Polk & Wardwell and Global Law Office are advising medical research firm CARsgen Therapeutics on its planned IPO in Hong Kong, with Herbert Smith Freehills and Zhong Lun Law Firm advising the joint underwriters. The IPO is expected to raise up to $400 million.

CARsgen is a biopharmaceutical company established in 2014, with operations in China and the U.S. It focuses on CAR-T cell therapies for the treatment of hematological malignancies and solid tumors.

Maples and Calder is providing the issuer offshore legal advice. The joint underwriters are Goldman Sachs and UBS.

Related Articles

Deals

CC, Davis Polk act on ChaPanda’s $330 mln Hong Kong IPO

by Charlie Wu 吴卓言 |

Davis Polk & Wardwell and Jingtian & Gongcheng have advised Sichuan Baicha Baidao, a Chinese low-priced tea chain also known as ChaPanda, on its $330 million IPO on the Hong Kong Stock Exchange, with Clifford Chance and King & Wood Mallesons acting for the sponsor CICC and underwriters.

Deals

MoFo, Davis Polk lead on Ascendent’s $1.66 bln take-private bid for Hollysys

by Mari Iwata |

Morrison & Foerster and Zhong Lun Law Firm have advised Hong Kong-based private equity firm Ascendent Capital on its $1.66 billion bid to take Chinese automation control system provider Hollysys private. The latter is being represented by Davis Polk & Wardwell and Haiwen & Partners.

Deals

Davis Polk, Zhong Lun guiding Mixue’s billion-dollar HK IPO

by Mari Iwata |

Davis Polk & Wardwell and Zhong Lun Law Firm are advising China's largest bubble-tea chain store, Mixue Bingcheng, on its IPO on the Hong Kong Stock Exchange, which aims to raise between $500 million and $1 billion.